Amount of qualified sufferers: CDEC mentioned the uncertainty in the amount of patients with reasonably serious to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some individuals who are categorised as obtaining gentle or average disease can have a critical bleeding phenotype, https://hemgenix27048.blogkoo.com/5-easy-facts-about-hemgenix-described-55233493